ライフサイエンスコーパス: syngeneic

1 received bilateral orthotopic injections of syngeneic 67NR, 4T07, or 4T1cells (1 x 10(5) cells per i

2 determined after intravenous inoculation of syngeneic 9801L pancreas carcinoma cells.

3 simulated by using bone graft material from syngeneic ACTB-eGFP-expressing mice.

4 ed ASNase efficacy in mice transplanted with syngeneic ALL cells and, like in humans, without affecti

5 One patient underwent a syngeneic allograft and 25 HDM/ASCT (16 of whom subseque

6 DHB had no effect on the growth of syngeneic allografts in wild-type mice but opposed the a

7 Syngeneic and allogeneic cardiospheres attenuated the in

8 In vivo, cell engraftment was similar in the syngeneic and allogeneic groups 1 week and 3 weeks after

9 first days after embryo implantation in both syngeneic and allogeneic matings; express the markers of

10 s producing insulin after transplantation in syngeneic and allogeneic recipients.

11 B-cell reconstitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depl

12 t of an antibody-mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney transplant mo

13 expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lun

14 iferated more in response to Ag presented by syngeneic APC than the same T cell subset from healthy a

15 ce, C1q-deficient (C1qa(-/-)) mice bearing a syngeneic B16 melanoma exhibit a slower tumour growth an

16 ti-PD-L1, but not anti-CTLA4, therapy in the syngeneic B16F10 melanoma model.

17 udy, we show that the growth of transplanted syngeneic B16F10 melanoma or Lewis lung carcinoma cells

18 fails to generate antitumor immunity against syngeneic B16F10 tumors in mice.

19 In vivo, both a syngeneic (B6-to-B6) marginal mass islet transplant mode

20 e immunized against platelets from wild-type syngeneic BALB/c (CD61(+)/H-2(d)), allogeneic C57BL/6 (C

21 n of a GR9-B11 mouse fibrosarcoma clone into syngeneic BALB/c mice, all animals remained free of spon

22 pic breast cancer model using 4T1luc-bearing syngeneic BALB/c mice.

23 ration by dilution of transferred cells into syngeneic BALB/c recipients.

24 Our results demonstrate that syngeneic bile duct antigens efficiently break immune to

25 autoimmune cholangitis via immunization with syngeneic bile duct protein (BDP).

26 ansfer of T cells from transplanted nudes to syngeneic black-coated RAG(-/-) recipients caused progre

27 though CMV infection was self-limiting after syngeneic BMT, in the presence of GVHD after allogeneic

28 th equal potency to those administered after syngeneic BMT.

29 es the development of autoimmune disorder in syngeneic BMTs.

30 Using our syngeneic bone marrow transplant (BMT) mouse model, BMT

31 cells were repopulated to a normal level by syngeneic bone marrow transplantation.

32 on analyses combined with in vivo studies in syngeneic breast cancer models demonstrate the participa

33 In a syngeneic breast cancer mouse model overexpressing GLUT1

34 use HCC cells (Hepa1-6) were inoculated into syngeneic C57BL/6 mice, intratumoral injection of adenov

35 ies of the promising cationic amphiphiles in syngeneic C57BL/6J mice under prophylactic settings.

36 injected B16rho(0) mouse melanoma cells into syngeneic C57BL/6N(su9-DsRed2) mice that express red flu

37 We demonstrated that both allogeneic and syngeneic CAR T cells show initial expansion as effector

38 y of diabetes reversal of allogeneic but not syngeneic CC islets was lower than that of naked islets,

39 We have isolated two syngeneic cell lines (indolent and aggressive) through i

40 ntation of green fluorescent protein-labeled syngeneic colorectal cancer cells.

41 a diminished 5-FU therapeutic response in a syngeneic colorectal tumor model consistent with increas

42 the bacterial population dynamics in ectopic syngeneic colorectal tumours in mice via a luminescent r

43 compared to 93% (71-104) and 82% (59-90) in syngeneic controls (P=0.006 and 0.03).

44 Compared with syngeneic controls, RIC mice with GVHD showed evidence o

45 d from draining lymph nodes of allogeneic or syngeneic corneal transplanted BALB/c mice.

46 ed inflammation when they were recipients of syngeneic corneal transplants but also exhibited signifi

47 d intracoronarily vehicle or 1 million male, syngeneic CPCs.

48 ltivalent M2pep and M2pepKLA analogs using a syngeneic CT-26 tumor cell suspension.

49 Consistent with these advantages, in syngeneic CT26 tumor models, high-affinity PD-1 was effe

50 s, this original demonstration used congenic/syngeneic dam and foster pup pairs.

51 In a syngeneic DLBCL mouse model, this PARP1-targeted PET ima

52 ion of hapten conjugated to self-antigens of syngeneic erythrocytes and subsequent contact immunizati

53 specific STAT3-knockdown postnatal mice-plus syngeneic fibroblast cell-transplant models-we demonstra

54 sCD and tested in animal models of human and syngeneic GBM.

55 Similar growth inhibition was observed in syngeneic GL261 GBM (p < 0.05).

56 We treated mice bearing orthotopic syngeneic (Gl261) GBMs or human (MGG8) GBM xenografts wi

57 B signaling (p65) in myeloid cells inhibited syngeneic glioblastoma (GBM) through decreased CD45 infi

58 Furthermore, using a syngeneic glioma model, w-MWNT-ANG showed enhanced uptak

59 l survival of tumor-bearing mice in the GL26 syngeneic glioma model.

60 rates that resistance to MYXV virotherapy in syngeneic glioma models involves a multifaceted cellular

61 Finally, in mice harboring syngeneic gliomas, an inhibitor of 2HG synthesis complem

62 geneic grafts without cold ischemia time and syngeneic grafts did not develop any TV.

63 In contrast, syngeneic grafts in the same mice elicited transient and

64 he airway epithelium was mostly preserved in syngeneic grafts, mostly destroyed in the KCa3.1 and TRA

65 the survival or histology of DST/MR1-treated syngeneic heart grafts, the latter indicating that persi

66 cytomegalovirus (anti-MCMV) responses after syngeneic hematopoietic stem cell transplantation (HSCT)

67 Compound 3c almost eliminated the growth of syngeneic hepatocellular carcinoma in Balb/c mice, sugge

68 nificantly inhibited in vivo the growth of a syngeneic hepatocellular carcinoma in Balb/c mice.

69 ated events in the liver after transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-defic

70 In 2 syngeneic HER2+ self-antigen tumor models, we found that

71 In a syngeneic HLA-A2-transgenic mouse model of large establi

72 er cell line Panc02 into the pancreas of the syngeneic host C57BL/6.

73 developed murine models of this disease, in syngeneic hosts as well as in nonobese diabetic/severe c

74 51 days), and old (736 days) C57BL/6 mice as syngeneic hosts for engraftment of Lewis lung cancer to

75 In CD47-deficient syngeneic hosts, engrafted B16 melanomas were 50% more s

76 tive phenotypic traits after transmission to syngeneic hosts.

77 radiotherapeutic response in immunocompetent syngeneic hosts.

78 ive mammary cancer metastasis to the lung of syngeneic hosts.

79 ion gp96-Ig within 2 weeks of T cell-replete syngeneic HSCT led to cross-presentation and increased s

80 In syngeneic HSCT studies, (211)At-B10-30F11 RIT improved t

81 trate that human induced Treg cells suppress syngeneic human ILC2s through ICOSL to control airway in

82 l alterations in tumor cells in vitro and in syngeneic immune-competent mouse models.

83 phatic drainage from murine B16 melanomas in syngeneic, immune-competent C57Bl/6 mice is associated w

84 ompared with an otherwise identical IgG in a syngeneic immunocompetent animal, and we identify TNFalp

85 y, and immunosuppressive microenvironment in syngeneic immunocompetent mice and should prove useful f

86 otopic malignant gliomas were established in syngeneic immunocompetent mice and then treated with den

87 rexpression inhibited growth of HCC cells in syngeneic immunocompetent mice.

88 Here, using syngeneic immunocompetent mouse tumor models, we reveal

89 By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRgamma-chain knock

90 in-isolated microglia in treatment of murine syngeneic intracranial malignant gliomas.

91 T cell proliferation in vitro, rejection of syngeneic iPSC-derived EBs/tissue-specific cells (TSCs)

92 Thus, differentiated cells derived from syngeneic iPSCs do not appear to be rejected after trans

93 e of an immune response to undifferentiated, syngeneic iPSCs.

94 ockade leads to a significant improvement of syngeneic islet engraftment and of allogeneic islet graf

95 inflammatory response in islets and improve syngeneic islet graft survival in mice.

96 Diabetic mice were transplanted with syngeneic islets placed under the kidney capsule (KC) or

97 Six hundred syngeneic islets subcutaneously transplanted into the pr

98 etic C57BL/6 mice were transplanted with 350 syngeneic islets through the portal vein and treated onc

99 of suboptimal islet transplants of 50 or 125 syngeneic islets to achieve glycemic control in STZ-indu

100 plantation of a marginal mass (50 islets) of syngeneic islets treated with nanoparticle conjugates ta

101 xpression of TGF-beta prevented rejection of syngeneic islets, that there was reduction of dendritic

102 ols) were given subcutaneous injections of a syngeneic KPC-derived PDAC cell line.

103 iatrogenic interference), allogeneic but not syngeneic leukocytes could induce a rapid (after 1 d) ac

104 Syngeneic (LEW-LEW) (n = 4) and allogeneic (BN-LEW) (n =

105 acity in NFAT5-deficient macrophages against syngeneic Lewis lung carcinoma and ID8 ovarian carcinoma

106 In the syngeneic Lewis-to-Lewis rat model of kidney transplanta

107 used systemically to treat established BCL1 syngeneic lymphoma, and therapy is lost when using a mou

108 male mice of inbred strain CBA do not reject syngeneic male skin grafts even though they mount a T-ce

109 R4 blockade resulted in significantly better syngeneic marginal mass islet engraftment and in indefin

110 for mAb-induced therapy of both subcutaneous syngeneic melanoma and human breast cancer xenografts.

111 lidated a mouse model of endometriosis using syngeneic menstrual endometrial tissue introduced into t

112 lignancy (n = 5/group), the latter through a syngeneic metastasis approach.

113 cle for doxorubicin delivery (CP-Dox) in the syngeneic metastatic murine models 4T1 and Lewis lung ca

114 were subcutaneously injected into flanks of syngeneic mice and tumor growth was assessed.

115 vivo, it significantly enhances survival in syngeneic mice bearing intracerebral 005 tumors.

116 In syngeneic mice bearing two simultaneously implanted tumo

117 ailed to grow when transplanted into normal, syngeneic mice but grew progressively in immunosuppresse

118 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromised or Treg cell

119 is could be adoptively transferred to naive, syngeneic mice by CD4(+) T cells.

120 tly, we showed that generation of tumours in syngeneic mice by cells devoid of mitochondrial (mt) DNA

121 NAs against p63 into the mammary fat pads of syngeneic mice delays tumor growth in vivo.

122 Using syngeneic mice infected acutely or chronically with 6 di

123 vitro, and those cells were inoculated into syngeneic mice mammary fat pads.

124 r accomplishing robust anti-PDAC immunity in syngeneic mice through the induction of immunogenic cell

125 coma cells were injected into the spleens of syngeneic mice to isolate tumour sub-populations that co

126 ts in complete FC-muMCL1 tumor regression in syngeneic mice via NK- and T-cell-dependent mechanisms.

127 cle or PAHSA and splenic CD4(+) T cells from syngeneic mice were co-cultured to assess antigen presen

128 lls distributed predominantly to the lung of syngeneic mice, a frequent site of breast cancer metasta

129 d for tumor cells to grow and metastasize in syngeneic mice, a surprising finding given that other in

130 line recapitulated mast cell recruitment in syngeneic mice, demonstrating that this cell state can d

131 e tumorigenesis and lung metastasis model in syngeneic mice, depletion of LKB1 markedly increased tum

132 In obese syngeneic mice, metformin treatment mimicked the effects

133 cells were transplanted into 3-day wounds of syngeneic mice, only CD206(+)/CD301b(+) macrophages sign

134 In syngeneic mice, shikonin and cisplatin together, but not

135 the growth of transplantable B16 melanoma in syngeneic mice, which is accompanied by enhanced antitum

136 uced lymphatic dissemination of EMT cells in syngeneic mice.

137 are directly implanted into the left lobe of syngeneic mice.

138 in a triple-negative 4T1 breast carcinoma in syngeneic mice.

139 ble in a cohort of contemporaneously housed, syngeneic mice.

140 tic leukemia when infused into unconditioned syngeneic mice.

141 tch in species but, surprisingly, also for a syngeneic mismatch in sex.

142 tion-induced (10 Gy) tumor growth delay in a syngeneic model (C3H) but not immunosuppressed (Nu/Nu) s

143 In vivo, 4i in a mouse syngeneic model demonstrated high antitumor activity whi

144 eatment in immune competent mice utilizing a syngeneic model of mammary tumor growth in FVB mice.

145 In a syngeneic model of melanoma brain metastasis, a combinat

146 total activity for (177)Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer.

147 tivity resulted in the highest efficacy in a syngeneic model of murine prostate cancer.

148 We previously showed that ID8, a widely-used syngeneic model of ovarian cancer, lacked any of the fre

149 r development was investigated using the ID8 syngeneic model of ovarian cancer.

150 culminating in improvement in survival in a syngeneic model of ovarian peritoneal carcinomatosis.

151 In a syngeneic model of tumor progression, subcutaneous injec

152 tastatic gene signature' derived from murine syngeneic model predicts poor patient survival in the ma

153 inst established B cell lymphoma in a BALB/c syngeneic model system.

154 apparent body weight loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.

155 C57BL/6J (allogeneic model, n = 17) and C3H (syngeneic model, n = 13) mice.

156 In a syngeneic model, similarly engineered melanoma-reactive

157 I-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent, and more s

158 ls rendered protection against melanoma in a syngeneic model, with decreased expression of PD-L1 and

159 effects of CD47 blockade were greater in the syngeneic model.

160 ompared these activities using two different syngeneic models for normal and oncogene-transformed hum

161 d (AP20187) triggered apoptosis in 2 in vivo syngeneic models of bone tumor growth in which apoptosis

162 g in mice enhances antitumor immunity in two syngeneic models of cancer.

163 and type II natural killer T (NKT) cells in syngeneic models of colorectal and renal cancer.

164 h and prolong survival in both xenograft and syngeneic models of glioblastoma.

165 n mouse triple-negative breast cancer (TNBC) syngeneic models with a TGI (tumor growth inhibition) of

166 antitumor efficacy of immunomodulator Abs in syngeneic models.

167 e compared more than 3700 compounds in three syngeneic mouse embryonic stem cell (mESC) lines: htt(-/

168 d in synergistic activity in two independent syngeneic mouse glioma models by promoting migration of

169 ortalized normal human astrocytes (NHAs) and syngeneic mouse glioma models, the introduction of mutan

170 tempered by evidence that undifferentiated, syngeneic mouse iPSCs are immunogenic upon transplantati

171 Syngeneic mouse islets (150) were transplanted either un

172 Syngeneic mouse islets were transplanted subcutaneously

173 iability probe to immune cells isolated from syngeneic mouse MB49 bladder tumors, spleens, and tumor-

174 icle-encapsulated paclitaxel in subcutaneous syngeneic mouse melanoma and orthotopic xenograft lung c

175 istently, inflammatory MITF(low)/c-Jun(high) syngeneic mouse melanomas recruit myeloid immune cells i

176 high metastatic potential and an orthotopic syngeneic mouse model and in vitro using a CXCR2 small-m

177 mor activity of K145 was also confirmed in a syngeneic mouse model by implanting murine breast cancer

178 Using a syngeneic mouse model for GB, we tested whether local de

179 vivo, tumors were induced in an orthotopic, syngeneic mouse model of advanced stage EOC.

180 In this study, we used a syngeneic mouse model of BRAF(V600E)-driven melanoma to

181 In a syngeneic mouse model of endometriosis, IL-33 injections

182 In a syngeneic mouse model of glioblastoma, administering TGF

183 -FAK mechanosignaling and Akt signaling in a syngeneic mouse model of metastasis.

184 2 displayed potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolonged

185 riggered complete regressions in the Ehrlich syngeneic mouse model of solid tumor.

186 An orthotopic syngeneic mouse model resulted in tumours with 2.3-fold

187 e experimental lung metastasis model and the syngeneic mouse model.

188 osis using patient samples, cell lines and a syngeneic mouse model.

189 copal effects on both 4T1 and TUBO bilateral syngeneic mouse models further demonstrate that ZnP@pyro

190 Using syngeneic mouse models of breast cancer, melanoma, and c

191 upregulation on tumor cells in a variety of syngeneic mouse models of cancer.

192 eriments and mouse transcriptome analyses in syngeneic mouse models, we provide evidence that tumour-

193 ced neovascularization using two independent syngeneic mouse models.

194 the lung and liver in multiple xenograft and syngeneic mouse models.

195 y report complete regression of tumors using syngeneic mouse models.

196 and therapeutic efficacy of PD-1 blockade in syngeneic mouse models.

197 es displayed equal oncolytic efficacies in a syngeneic mouse myeloma model.

198 grees C in UW solution, were transplanted to syngeneic mouse recipients.

199 n of 10(6) 5T33 mouse myeloma cells into the Syngeneic mouse strain C57BL/KaLwRij resulted in a rapid

200 nation with a clinical chemotherapeutic to a syngeneic mouse transplantation model of hepatic colorec

201 aded LPS-Lips in HepG2 cells in vitro and in syngeneic mouse transplants in vivo.

202 , and oral RA190 treatment retarded HPV16(+) syngeneic mouse tumor growth, without affecting spontane

203 Using an orthotopic syngeneic mouse tumor model, we make the striking observ

204 In syngeneic mouse tumor models, 1F5 showed potent antitumo

205 survival improvements are achieved in three syngeneic mouse tumor models, including complete respons

206 in the tumor microenvironment using several syngeneic mouse tumor models.

207 lines, we performed a secondary screen in a syngeneic murine AML model driven by the MLL-AF9 oncogen

208 Dox-LTSLs were injected intravenously into a syngeneic murine breast cancer model (6 mg Dox/kg body w

209 tivity of tumor-associated immune cells in a syngeneic murine breast cancer model.

210 The heterotopic syngeneic murine head and neck cancer model (mEER) cause

211 a in vitro and in vivo in KIR transgenic and syngeneic murine lymphoma models.

212 ccine-induced antitumor immune response in a syngeneic murine model of B16 melanoma.

213 in the process of glioma progression in the syngeneic murine model of glioma.

214 Using a syngeneic murine model, we investigated the changes that

215 ays, alternative methods of quantitation and syngeneic murine models have all led to an appreciation

216 in a physiologic setting, using preclinical, syngeneic murine models of hematologic malignancies and

217 Both in vitro and in vivo in syngeneic murine models of islet transplantation, the fu

218 esmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancers in an immune-indepen

219 In syngeneic murine rhabdomyosarcoma models, we found that

220 opically implanted human tumor xenograft and syngeneic murine tumor models.

221 Tumor targeting of DAB4 was selective for syngeneic murine tumors and for human tumor xenografts o

222 dritic cell vaccines in two different murine syngeneic murine tumors.

223 ntraportally with 2500 ferucarbotran-labeled syngeneic (n=10) or allogeneic (n=12) islet equivalents

224 ls are similarly capable to polarize ex vivo syngeneic naive CD4(+) T cells toward a T-bet(+)IFN-gamm

225 oietic stem/progenitor cells into irradiated syngeneic or allogeneic young or aged recipients resulte

226 cts were elicited by 3'3'-cGAMP injection in syngeneic or immunodeficient mice grafted with multiple

227 oma (CTCL) lines, HH and Hut78, were used in syngeneic or standard NSG mouse models to demonstrate a

228 ses PDAC tumour cell growth in xenograft and syngeneic orthotopic animal models, and induces growth i

229 Here we describe a syngeneic orthotopic HCC model in immunocompetent mice w

230 In an in vivo syngeneic orthotopic model, inhibition of TGF-beta signa

231 cells in the tumor microenvironment, using a syngeneic orthotopic mouse model of epithelial ovarian c

232 We also used a syngeneic orthotopic PDAC mouse model to study tumor gro

233 ncreased survival in both obesity-driven and syngeneic orthotopic PDAC mouse models.

234 Here, we used a syngeneic, orthotopic mouse model of breast cancer to st

235 Using two different syngeneic, orthotopic tumor implant models of breast can

236 therapeutic response in an in vivo primary, syngeneic p53(null) claudin-low tumor model that is norm

237 H mutations in immune response, we created a syngeneic pair mouse model for mutant IDH1 (muIDH1) and

238 e Her2/Neu-driven breast cancer model and in syngeneic pancreatic tumor (Pan02) xenografts.

239 Here, we analyzed 2 syngeneic primary human osteosarcoma cell lines that exh

240 ction of Mobilan into subcutaneously growing syngeneic prostate tumors in immunocompetent hosts impro

241 antagonist, etanercept (ETN), for studies in syngeneic rat hepatocyte transplantation systems.

242 ntly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equi

243 rgeting the Lewis Y antigen over 7 d using a syngeneic rat model of colon carcinoma.

244 In vivo experiments were conducted using a syngeneic rat orthotopic CCA model.

245 We used a syngeneic rat renal transplantation model of IRI with bi

246 widely on human ovarian tumors, along with a syngeneic rat tumor model expressing human FRalpha.

247 livers, characterized, and transplanted into syngeneic recipients.

248 tion and subsequent associated graft loss in syngeneic recipients.

249 mune disease that leads to severe wasting in syngeneic recipients.

250 n vitro and after their transplantation into syngeneic recipients.

251 e UW solution for 20 h, were transplanted to syngeneic recipients.

252 ed of autophagosomes (DRibbles) derived from syngeneic sarcomas could induce cross-reactive T-cell re

253 eneic skin transplantation alone (n = 6), or syngeneic skin transplantation (n = 4).

254 Syngeneic spontaneous and experimental metastasis models

255 abeled TPP is continuously internalized into syngeneic, spontaneous, chemically/genetically induced a

256 microenvironment role of RAGE, we performed syngeneic studies with orthotopically injected breast ca

257 Here, we utilized a syngeneic subcutaneous murine model of B16F10 melanoma t

258 alloreactive T cells and was not observed in syngeneic T cells during homeostatic proliferation.

259 ultaneous transfer of genetically engineered syngeneic T cells expressing a chimeric antigen receptor

260 the role of BLT1 in antitumor immunity using syngeneic TC-1 cervical cancer model, and observed accel

261 fragmentation one week before engraftment of syngeneic TC1 or LL3 tumor cells and tumor analysis four

262 essive myeloid-derived suppressor cells in a syngeneic TNBC mouse model.

263 Using a syngeneic TP53-null mouse model of breast cancer, we ide

264 Syngeneic transplant experiments utilizing green fluores

265 duced more VEC proliferation than those from syngeneic transplant recipients (P = 0.03).

266 fting to LSC-deficient mice in xenogeneic or syngeneic transplantation models.

267 at P2X1R is augmented in both allogeneic and syngeneic transplantation.

268 enic changes appeared due to conditioning or syngeneic transplantation.

269 ate tumorigenic from nontumorigenic cells in syngeneic transplants.

270 rradiated and transplanted 3 days later with syngeneic Trp53-null mammary fragments.

271 y (5 weeks) or at maturation (10 weeks) with syngeneic Trp53-null mammary tissue fragments and monito

272 two in vivo experimental systems: an ectopic syngeneic tumor (Lewis lung carcinoma) and an orthotopic

273 ytokine response and potent cytotoxicity for syngeneic tumor cells upon activation, as do human CD8al

274 -CpG-B could substantially protect mice from syngeneic tumor challenge, even after 4 mo of vaccinatio

275 Further, syngeneic tumor experiments revealed that the absence of

276 pression within T cells is required to limit syngeneic tumor growth and promote IFNgamma production b

277 r-infiltrating CD8 expression in preclinical syngeneic tumor immunotherapy models including antigen-s

278 PHD3 overexpression in a syngeneic tumor model resulted in fewer liver metastases

279 ement membrane, whereas its attenuation in a syngeneic tumor model resulted in reduced metastatic col

280 demonstrate that, in three different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the

281 ne cells to eliminate large tumor burdens in syngeneic tumor models and a genetically engineered mous

282 sed metastatic dissemination in xenograft or syngeneic tumor models in vivo.

283 and inflammatory analysis of four additional syngeneic tumor models revealed that tumors can induce f

284 any of the effects of anti-mouse GITR mAb in syngeneic tumor models, decreasing both Treg numbers and

285 imaging inflammation in both xenogeneic and syngeneic tumor models, which resulted in detection of t

286 plete protection from tumor engraftment in a syngeneic tumor vaccine model, inhibited neutrophil extr

287 mes was similar to non-targeted liposomes in syngeneic tumor-bearing FVB mice and C-LPP liposomes red

288 The peptides were injected into rats with syngeneic tumors and mice with orthotopic or xenograft t

289 y was CD8 dependent and controlled growth of syngeneic tumors even when an adoptive immunotherapy was

290 C57BL6/KaLwRij mice bearing murine 5TGM1-GFP syngeneic tumors generated after intravenous injection v

291 ring peritoneal MKN-45P xenografts and CT-26 syngeneic tumors with IP linTT1-D(KLAKLAK)2-NWs resulted

292 tivity in orthotopic human tumor xenografts, syngeneic tumors, and a genetic model of pancreatic canc

293 within T cells during the immune response to syngeneic tumors.

294 munotargeting of xCT in mice challenged with syngeneic tumorsphere-derived cells delayed established

295 es and this correlated with no difference in syngeneic tumour growth between wild-type, Claudin 14-he

296 ma model SMA560 injected intracranially into syngeneic VM/Dk mice, analyzing animals at various posti

297 plantation (major histocompatibility complex syngeneic) was modeled by transplanting hearts from A-Tg

298 The stroke phenotype can be transferred to syngeneic wild-type mice via Tgfbr2(Myeko) bone marrow t

299 is in experimental as well as in spontaneous syngeneic wild-type mouse models.

300 lls are directly implanted into the lungs of syngeneic WT mice or mice globally deficient in 5-LO (5-